ENZ Enzo Biochem Inc

  1. Stocks
  2. Healthcare
  3. NYSE: ENZ

Price (delayed)

$1.09

Market cap

$55.84M

P/E Ratio

1.63

Dividend/share

N/A

EPS

$0.67

Enterprise value

$2.7M

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous ...

Highlights
The company's revenue has surged by 196% YoY and by 9% QoQ
Enzo Biochem's net income has soared by 192% YoY and by 34% from the previous quarter
ENZ's equity has soared by 116% YoY but it is down by 4.7% from the previous quarter
Enzo Biochem's debt has shrunk by 62% YoY but it has increased by 2.2% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.enzo.com
Peers: RDNT DGX NEO LH

Key stats

What are the main financial stats of ENZ
Market
Shares outstanding
51.23M
Market cap
$55.84M
Enterprise value
$2.7M
Valuations
Price to earnings (P/E)
1.63
Price to book (P/B)
0.78
Price to sales (P/S)
4.3
EV/EBIT
0.08
EV/EBITDA
0.08
EV/Sales
0.21
Earnings
Revenue
$12.81M
EBIT
$31.95M
EBITDA
$33.74M
Free cash flow
-$45.92M
Per share
EPS
$0.67
Free cash flow per share
-$0.91
Book value per share
$1.4
Revenue per share
$0.25
TBVPS
$1.96
Balance sheet
Total assets
$99.08M
Total liabilities
$28.3M
Debt
$7.11M
Equity
$70.78M
Working capital
$55.64M
Liquidity
Debt to equity
0.1
Current ratio
3.2
Quick ratio
2.59
Net debt/EBITDA
-1.57
Margins
EBITDA margin
263.5%
Gross margin
112.3%
Net margin
254.3%
Operating margin
-74.2%
Efficiency
Return on assets
32.6%
Return on equity
53.7%
Return on invested capital
151.9%
Return on capital employed
43.3%
Return on sales
249.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENZ stock price

How has the Enzo Biochem stock price performed over time
Intraday
-3.54%
1 week
-6.84%
1 month
-11.38%
1 year
-54.96%
YTD
-21.58%
QTD
-14.17%

Financial performance

How have Enzo Biochem's revenue and profit performed over time
Revenue
$12.81M
Gross profit
$14.38M
Operating income
-$9.51M
Net income
$32.57M
Gross margin
112.3%
Net margin
254.3%
The company's revenue has surged by 196% YoY and by 9% QoQ
Enzo Biochem's net income has soared by 192% YoY and by 34% from the previous quarter
The operating income has soared by 58% YoY and by 20% from the previous quarter
The operating margin has grown by 26% from the previous quarter

Growth

What is Enzo Biochem's growth rate over time

Valuation

What is Enzo Biochem stock price valuation
P/E
1.63
P/B
0.78
P/S
4.3
EV/EBIT
0.08
EV/EBITDA
0.08
EV/Sales
0.21
The EPS has soared by 192% YoY and by 34% from the previous quarter
ENZ's equity has soared by 116% YoY but it is down by 4.7% from the previous quarter
The P/B is 66% less than the last 4 quarters average of 2.3 and 63% less than the 5-year quarterly average of 2.1
The company's revenue has surged by 196% YoY and by 9% QoQ
The P/S is 72% above the 5-year quarterly average of 2.5

Efficiency

How efficient is Enzo Biochem business performance
ENZ's ROA has soared by 179% year-on-year and by 26% since the previous quarter
ENZ's ROE has soared by 174% YoY and by 13% QoQ
The ROIC has soared by 77% from the previous quarter
The ROS has grown by 20% from the previous quarter

Dividends

What is ENZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENZ.

Financial health

How did Enzo Biochem financials performed over time
The current ratio has soared by 183% YoY and by 4.9% from the previous quarter
The total liabilities has contracted by 35% YoY and by 12% from the previous quarter
Enzo Biochem's debt is 90% lower than its equity
ENZ's equity has soared by 116% YoY but it is down by 4.7% from the previous quarter
The debt to equity has plunged by 82% YoY but it has grown by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.